 | | Vol. 12.22 – 8 June, 2021 |
| |
|
|
| The ex vivo delivery of mRNA encoding the base editor with a targeting guide RNA into hematopoietic stem and progenitor cells from patients with sickle cell disease (SCD) resulted in 80% conversion of the SCD allele to into Makassar β-globin, a non-pathogenic variant.
[Nature] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| The transcription factor ATF3 coordinated serine and nucleotide metabolism to maintain cell cycling, survival, and the differentiation blockade in acute myeloid leukemia.
[Molecular Cell] |
|
|
|
| Scientists identified that tumor necrosis factor receptor-associated factor 2 knockdown/knockout in multiple myeloma cells mediated immunomodulatory drug resistance via activation of noncanonical nuclear factor κB and extracellular signal-regulated kinase (ERK) signaling.
[Science Advances] |
|
|
|
| Investigators reported that mixed lineage kinase domain-like protein (MLKL) contributed to the cellular differentiation of transformed hematopoietic progenitor cells in acute myeloid leukemia by controlling the release of granulocyte colony-stimulating factor (G-CSF) from leukemic progenitor cells.
[Cell Death & Differentiation] |
|
|
|
| Researchers investigated the mechanism by which Ehrlichia chaffeensis acquires iron in the host cells, causing human monocytic ehrlichiosis.
[Proceedings of the National Academy of Sciences of the United States of America] |
|
|
|
| Scientists identified a serial of genes including NEK2, RARα2, which induced multiple myeloma (MM) proliferation and drug-resistance resulting in MM relapse and poor outcome.
[Haematologica] |
|
|
|
| With the hypothesis that granulocyte colony-stimulating factor has different effects on different types of hematopoietic stem cells, researchers performed serum-free single-cell culture and competitive repopulation with cultured cells.
[Haematologica] |
|
|
|
| The authors presented a miniaturized bone marrow tissue model that provided a screening bioreactor for personalized, pre-treatment response prediction to Eltrombopag for patients with thrombocytopenic disorders.
[eLife] |
|
|
|
| Investigators found that Gata2-L359V mutation impeded hematopoietic differentiation in murine embryonic and adult hematopoiesis and blocked murine chronic myeloid leukemia cell differentiation.
[Cell Death & Disease] |
|
|
|
| Researchers delineated and functionally validated the epigenomic network regulated by KDM4A, and showed that selective loss of KDM4A was sufficient to induce apoptosis in a broad spectrum of human acute myeloid leukemia cells.
[Cell Death & Disease] |
|
|
|
| Scientists utilized an imaging-based high-throughput system to identify chemical compounds that triggered enucleation of human erythroid cell lines and identified multiple histone deacetylase inhibitors inducing enucleated cells from the cell line.
[Communications Biology] |
| |
|
|
| The authors reported on 382 COVID-19 patients having undergone allogeneic or autologous hematopoietic cell transplantation reported to the European Society for Blood and Marrow Transplantation (EBMT) or to the Spanish Group of Hematopoietic Stem Cell Transplantation (GETH).
[Leukemia] |
|
|
|
| Investigators collected samples before and after allogeneic hematopoietic stem cell transplantation from two independent prospective cohorts and investigated the prognostic impact of amplicon-based next-generation sequencing-based assessment.
[Blood Cancer Journal] |
|
|
|
|
| Scientists evaluate the investigation of isocitrate dehydrogenase (IDH) inhibitors in combination with standard therapies such as azacytidine, with intensive chemotherapy, and with other small molecule targeted therapies in rational combinations to further improve clinical efficacy as therapies for acute myeloid leukemia.
[Blood Cancer Journal] |
|
|
|
| The authors summarize the role of CXCR4 in progression and treatment of acute leukemia, and discuss the potential value of using CXCR4 antagonists as immunosensitizer for graft-vs-leukemia effects of allogeneic HSC transplantation.
[Cell Proliferation] |
|
|
|
|
| MorphoSys AG and Constellation Pharmaceuticals, Inc. announced that they have entered into a definitive agreement whereby MorphoSys will acquire Constellation, a biopharmaceutical company developing novel therapeutics for myelofibrosis and hematological tumors.
[MorphoSys AG] |
|
|
|
| Johnson & Johnson is walking away from a $1.6 billion blood cancer medicine deal with Belgium’s argenx for the CD70-targeting cusatuzumab.
[Johnson & Johnson (Questex, Inc.)] |
|
|
|
|
| June 21 – 22, 2021
Virtual |
|
|
|
|
|
| | UT Southwestern Medical Center – Dallas, Texas, United Statess |
|
|
|
| | Medical College of Wisconsin – Milwaukee, Wisconsin, United States |
|
|
|
| | University of British Columbia – Vancouver, British Columbia, Canada |
|
|
|
| | Memorial Sloan Kettering Cancer Center – New York, New York, United States |
|
|
|
| | The University of Edinburgh – Edinburgh, Scotland, United Kingdom |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
